Business Context and Reporting Period
Company: Artiva Biotherapeutics, Inc. (Nasdaq: ARTV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Artiva is a clinical-stage biopharmaceutical company developing off-the-shelf, allogeneic natural killer (NK) cell-based therapies for autoimmune diseases. The company has no products approved for commercial sale and has incurred net losses since inception. Its lead product candidate, AlloNK (AB-101), is in clinical development for refractory rheumatoid arthritis (RA) and other B-cell driven autoimmune diseases.
Key Financial Metrics
| Metric (in thousands, except per share) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(48,521) | $(41,565) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(1.51) | $(1.71) | N/A |
| Total Operating Expenses | $51,320 | $44,982 | N/A |
| Cash, Cash Equivalents & Investments | N/A | N/A | $349,394 |
| Accumulated Deficit | N/A | N/A | $(379,070) |
| Net Cash Used in Operating Activities | $(41,305) | $(42,824) | N/A |
| Net Cash Provided by Financing Activities | $283,157 | $167 | N/A |
Material Changes vs. Prior Period
- Capital Raise: In May 2026, the company completed a public offering of common stock and pre-funded warrants, generating gross proceeds of $300.0 million and net proceeds of $282.7 million. This significantly increased cash balances from $26.7 million (Dec 31, 2025) to $301.5 million (June 30, 2026).
- Operating Expenses: Total operating expenses increased by $6.3 million (14%) to $51.3 million for the six months ended June 30, 2026, compared to $45.0 million in the prior year period. This was driven primarily by a $5.5 million increase in external research and development (R&D) costs related to the AlloNK clinical trials.
- Net Loss: Net loss increased by $6.9 million to $48.5 million, primarily due to higher R&D expenses, partially offset by interest income.
- Share Count: Weighted-average shares outstanding increased significantly due to the May 2026 offering, impacting dilution metrics.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The company announced positive initial clinical data for AlloNK in refractory RA, Sjögren's disease, and systemic sclerosis. More than 70 autoimmune patients have been treated across ongoing trials.
- Regulatory Status: In June 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK for refractory RA. The company has aligned with the FDA on a single registrational randomized controlled trial design expected to enroll approximately 150 patients.
- Timeline: The registrational trial is expected to initiate in the second half of 2026, with primary efficacy data reported in the second half of 2028 and a potential Biologics License Application (BLA) submission in 2029.
- Liquidity: Management believes existing cash, cash equivalents, and investments ($349.4 million) are sufficient to fund planned operations into 2029.
Risks and Contingencies
- Need for Additional Capital: Despite the recent funding, the company expects to incur significant losses for the foreseeable future and may require additional financing to complete development and commercialization.
- Clinical Trial Risks: As a clinical-stage company with no approved products, success depends on the safety and efficacy of AlloNK. Clinical trials are expensive, time-consuming, and have uncertain outcomes.
- Manufacturing: The company relies on its own facility and third-party manufacturers (including GC Cell). Disruptions in supply or manufacturing quality could delay trials.
- Regulatory Uncertainty: No NK cell-based therapy has been approved for autoimmune diseases. Regulatory pathways are evolving, and approval is not guaranteed.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $349.4 million cash balance against the projected burn rate and the timeline for the Phase 3 trial initiation and data readout.
- Clinical Data: Review the full dataset regarding the ACR50 response rates and safety profile (specifically cytokine release syndrome and neurotoxicity) for the 21 refractory RA patients mentioned.
- Manufacturing Capacity: Assess the scalability of the San Diego manufacturing facility and the reliability of third-party supply chains for cord blood and reagents.
- Dilution Impact: Analyze the impact of the May 2026 offering (23.9 million shares + pre-funded warrants) on existing shareholder ownership and future financing needs.
- Regulatory Alignment: Confirm the specific endpoints and design of the FDA-aligned Phase 3 trial to ensure it meets the criteria for RMAT designation benefits.